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Abstract
The underlying neurobiological basis of major depressive disorder remains elusive due to the severity, complexity, and 
heterogeneity of the disorder. While the traditional monoaminergic hypothesis has largely fallen short in its ability to 
provide a complete picture of major depressive disorder, emerging preclinical and clinical findings suggest that dysfunctional 
glutamatergic neurotransmission may underlie the pathophysiology of both major depressive disorder and bipolar depression. 
In particular, recent studies showing that a single intravenous infusion of the glutamatergic modulator ketamine elicits fast-
acting, robust, and relatively sustained antidepressant, antisuicidal, and antianhedonic effects in individuals with treatment-
resistant depression have prompted tremendous interest in understanding the mechanisms responsible for ketamine’s 
clinical efficacy. These results, coupled with new evidence of the mechanistic processes underlying ketamine’s effects, have 
led to inventive ways of investigating, repurposing, and expanding research into novel glutamate-based therapeutic targets 
with superior antidepressant effects but devoid of dissociative side effects. Ketamine’s targets include noncompetitive 
N-methyl-D-aspartate receptor inhibition, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid throughput potentiation 
coupled with downstream signaling changes, and N-methyl-D-aspartate receptor targets localized on gamma-aminobutyric 
acid-ergic interneurons. Here, we review ketamine and other potentially novel glutamate-based treatments for treatment-
resistant depression, including N-methyl-D-aspartate receptor antagonists, glycine binding site ligands, metabotropic 
glutamate receptor modulators, and other glutamatergic modulators. Both the putative mechanisms of action of these agents 
and clinically relevant studies are described.
Keywords: antidepressants, glutamate receptors, ketamine, treatment-resistant depression
Introduction
Major depressive disorder (MDD) is associated with global 
morbidity leading to costly psychiatric care and significant 
societal burden, with a commensurate impact on public health 
(Whiteford et al., 2013). Worldwide, more than 300 million peo-
ple now live with depression, a staggering increase of over 
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18% between 2005 and 2015. Workplace costs associated with 
depression-related disability further add to the global burden of 
the disease, as do suicide-related expenditures (Greenberg et al., 
2015). Indeed, MDD is the leading cause of suicide in the United 
States.
Standard pharmacological treatments for depression pres-
ently revolve around monoaminergic-based targets due to the 
early serendipitous discovery that drugs inhibiting the reuptake 
or metabolism of monoaminergic neurotransmitters (seroto-
nin, noradrenaline, dopamine) possess antidepressant effects 
(Bunney and Davis, 1965; Schildkraut, 1965; Heninger et  al., 
1996). However, despite their widespread use, the efficacy of 
these agents is limited by delayed therapeutic onset, low remis-
sion rates, and increased treatment refractoriness (Rush et al., 
2006; McIntyre et al., 2014). For instance, the large NIMH-funded 
Sequenced Treatment Alternatives to Relieve Depression study 
found that only one-third of MDD patients achieved remis-
sion after an adequate trial with a traditional antidepressant. 
Furthermore, even after 2 additional levels of antidepressant 
switch therapy or augmentation treatment, only two-thirds of 
patients achieved remission; thus, roughly 35% of patients in the 
Sequenced Treatment Alternatives to Relieve Depression study 
were nonremitters, a group described as having treatment-
resistant depression (TRD) (Trivedi et  al., 2006). Similarly, the 
remission rate in the recently completed Prolonging Remission 
in Depressed Elderly study was only 61%, despite the fact that 
the study used additional effective interventions such as elec-
troconvulsive therapy (Kellner et al., 2016a, b; Rasmussen, 2017).
A large proportion of the global burden of depression 
described above is attributable to TRD, which accounts for 
roughly one-third of depressed subjects. While a number of 
methods for assessing TRD exist (Malhi and Byrow, 2016), it 
is loosely defined as failure to respond to one or more FDA-
approved antidepressant treatments as measured via vari-
ous criteria, most often the Antidepressant Treatment History 
Form (Sackeim, 2001); it should be noted that in the context of 
this paper, TRD refers to treatment resistance to standard anti-
depressants only. TRD is associated with poorer overall clini-
cal outcomes, significant physical and mental comorbidities, 
a substantial burden on individuals and their families, high 
healthcare costs, and marked and protracted functional impair-
ment (Fekadu et  al., 2009; Culpepper, 2011). Lack of response 
to antidepressant therapy in general—and for TRD patients 
in particular—is also associated with increased suicide risk 
(Machado-Vieira et al., 2009). Current therapeutics have limited 
efficacy in treating suicidal ideation, and no FDA-approved med-
ications exist for that purpose (Griffiths et al., 2014). As a result, 
new trends in polypharmacy for MDD have been conceived in 
the last few years, particularly for treating chronic and severe 
forms of TRD, underscoring the critical unmet medical need for 
new agents with novel mechanisms of action that show rapid 
antidepressant efficacy (Olin et al., 2012).
In recent years, compelling evidence has accrued in favor 
of the glutamatergic system as a primary mediator of psychi-
atric pathology and a target for the therapeutic action of drugs, 
particularly rapid-acting antidepressants (Sanacora et al., 2008, 
2012; Duman and Aghajanian, 2012; Musazzi et al., 2013; Duman 
et al., 2016; Lener et al., 2017; Murrough et al., 2017a). Although 
glutamate was not recognized as a neurotransmitter until the 
1980s—when monoaminergic pathways had already been 
mapped in the brain—this excitatory amino acid is the most 
abundant neurotransmitter in the brain. Early clinical find-
ings suggested that glutamate plasma levels were significantly 
higher in patients with mood disorders (Altamura et al., 1993; 
Sanacora et al., 2008). In this context, emerging preclinical and 
clinical evidence of the impaired relationship between gluta-
matergic neurotransmission and synaptic plasticity in mood 
disorders has guided the search for novel pharmacotherapeutic 
strategies.
Towards this end, the glutamatergic agent ketamine has 
been intensely investigated over the past 2 decades. Ketamine’s 
antidepressant effects are hypothesized to be mediated by 
direct and indirect N-methyl-D-aspartate receptor (NMDAR) 
inhibition, gamma aminobutyric acid (GABA)-ergic interneuron 
disinhibition, and conversion to hydroxynorketamine (HNK) 
metabolites; together, these processes increase presynaptic glu-
tamate release, with the net effect of enhancing glutamatergic 
throughput at the α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid receptor (AMPAR) relative to the NMDAR (Zanos 
et al., 2016, 2018a). These presumed mechanisms are not mutu-
ally exclusive and may in fact work in a complementary fashion 
to exert sustained potentiation of excitatory synapses to main-
tain antidepressant response (Figure 1).
This article reviews the proposed mechanism of action of 
ketamine and other glutamatergic-based drugs used in TRD as 
well as the clinical evidence supporting their use in depressive 
disorders. It focuses on proof-of-concept evidence drawn from 
clinical studies of novel glutamate-modulating agents for TRD, 
including NMDAR antagonists, glycine site ligands, metabo-
tropic glutamate receptor modulators, and other glutamatergic-
modulating treatments.
NMDAR Antagonists
Ketamine’s Mechanism of Action: Overview
In recent years, ketamine’s mechanism of action has been widely 
studied not only as a tool to understand the nature of rapid anti-
depressant action and identify new therapeutic targets, but also 
in an attempt to better understand the basic neurobiological 
underpinnings of stress-related psychopathology (Monteggia 
et  al., 2014; Murrough et  al., 2017a; Zanos and Gould, 2018). 
Preclinical studies have been carried out using rodent stress 
models, most often using chronic stress protocols but occasion-
ally using acute stress. Since the early hypothesis of NMDAR 
inhibition of GABA interneurons (see below) was first formed, 
several different mechanisms have been proposed to explain 
ketamine’s antidepressant effects, not all of which are mutually 
exclusive (see Figure 1) (Li et al., 2010; Zanos and Gould, 2018). 
One of ketamine’s striking effects in rodents is its ability to rap-
idly (within 24 hours of administration) restore dendritic arbo-
rization and the density of synaptic spines reduced by chronic 
stress, an effect observed with traditional antidepressants after 
only weeks of treatment (Bessa et al., 2009; Morais et al., 2017). 
This effect coincides with the peak of ketamine’s antidepressant 
effects (24 hours) and is considered essential for its therapeutic 
actions (Duman and Aghajanian, 2012; Musazzi et al., 2017). In 
addition, this finding further validates the neuroplasticity/glu-
tamatergic hypothesis of depression, which posits that struc-
tural and functional disruption of glutamate synapses/circuitry 
is associated with stress-related psychopathology (Duman and 
Aghajanian, 2012; Sanacora et  al., 2012; Duman et  al., 2016; 
Murrough et al., 2017a). While a detailed analysis of all of ket-
amine’s proposed mechanisms of action is beyond the scope 
of this article, below we briefly review a number of different 
hypotheses and model mechanisms (Figure 1).
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Figure  1. Proposed mechanisms of action of glutamatergic modulators and other putative rapid-acting antidepressants. Disinhibition hypothesis: Ketamine and 
esketamine selectively block N-methyl-D-aspartate receptors (NMDARs). These are expressed on gamma-aminobutyric acid (GABA)-ergic inhibitory interneurons, and 
their blockade decreases interneuron activity that, in turn, leads to disinhibition of pyramidal neurons and enhanced glutamatergic firing. Glutamate then binds to 
and activates post-synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Inhibition of spontaneous NMDAR-mediated transmission: 
Alternatively, ketamine may induce rapid brain-derived neurotrophic factor (BDNF) translation in the hippocampus, reduce phosphorylation, and activate eukaryotic 
elongation factor 2 (eEF2). Ketamine may also preferentially bind to NMDARs and affect neuronal NMDAR-mediating spontaneous excitatory transmission, which at 
rest keeps eEF2 phosphorylated and inhibits BDNF synaptic translation. De-suppression of BDNF translation then contributes to changes in synaptic plasticity that 
mediate ketamine’s antidepressant effects. AMPAR activation is also necessary for these effects. Inhibition of extra-synaptic NMDARs: Ketamine selectively blocks 
extra-synaptic GluN2B-containing NMDARs, which are tonically activated by low levels of ambient glutamate regulated by the excitatory amino acid transporter 2 
(EAAT2) located on astrocytes. Inhibition of the extra-synaptic GluN2B-NMDARs de-suppresses mammalian target of rapamycin complex 1 (mTORC1) function, which 
in turn induces protein synthesis. Blockade of spontaneous NMDAR activation inhibits eEF2 kinase (eEF2K) activity, thus preventing phosphorylation of its eEF2 sub-
strate. This effect subsequently enhances BDNF translation and, ultimately, protein synthesis. Inhibition of lateral habenula (LHb) neurons: In animal models, local 
neuronal firing in a single brain region known as the lateral habenula (LHb) drives significant depressive-like behaviors. Ketamine decreases burst activity in the LHb 
by blocking NMDAR-dependent burst activity in the LHb and disinhibiting the downstream activity of midbrain dopaminergic neurons and serotoninergic neurons, 
which are responsible for activating the reward centers in the brain. Local blockade of NMDARs or low-voltage-sensitive T-type voltage sensitive calcium channels 
(T-VSCCs) in the LHb sufficed to induce rapid antidepressant effects. The role of ketamine metabolites: (2R,6R)-hydroxynorketamine (HNK) exerts NMDAR inhibition-
independent antidepressant actions by activating AMPAR-mediated synaptic potentiation.Other glutamatergic modulators: Metabotropic glutamate receptor (mGluR) 
2/3 antagonists are thought to enhance synaptic glutamate levels, thereby boosting AMPAR transmission and firing rates and extracellular monoamine levels. GLYX-13, 
which has partial agonist properties at NMDARs, is hypothesized to activate mTORC and subsequently induce protein synthesis. GLYX-13 requires AMPA and activity-
dependent BDNF release, but unlike ketamine does not produce glutamate bursts. AMPAR activation enhances BDNF release, activates the tropomyosin receptor kinase 
B (TrkB) receptor, and subsequently promotes protein synthesis by activating the mTORC complex. AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; GAD, 
glutamate decarboxylase; Gαs, G alpha subunits; Gln, glutamine; GLT-1, glutamate transporter 1; Glu, glutamate; GSK-3, glycogen synthase kinase 3; SNARE, soluble 
N-ethylmaleimide-sensitive factor attachment protein receptor. Adapted with permission from (Lener et al., 2017; Zanos et al., 2018a).
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Ketamine’s Mechanisms of Action:  
NMDAR-Dependent Mechanisms
Inhibition of NMDARs on GABA Interneurons
It has been postulated that, in the prefrontal cortex (PFC), keta-
mine preferentially blocks NMDARs on GABAergic interneurons, 
which, in turn, increases the firing of pyramidal neurons. This 
induces rapid and transient activation of mammalian target of 
rapamycin complex (mTORC) signaling and, in turn, increases 
the local expression of synaptic proteins (Arc, PSD-95, GluR1, 
and synapsin I), consistent with the timing observed for induc-
ing new spine synapses (Li et al., 2010). mTORC inhibition with 
rapamycin blocks ketamine’s effects. An essential effector of 
this rapid response is assumed to be brain derived neurotrophic 
factor (BDNF), a neurotrophin abundant in the adult brain that 
is produced and released at synapses in an activity-dependent 
fashion (Lu, 2003; Leal et al., 2014; Song et al., 2017). According 
to this hypothesis, the glutamate burst induced by ketamine 
increases AMPAR-mediated excitatory transmission, which, in 
turn, increases the release of BDNF at synapses and activates 
mTORC. Studies found that knockin mice carrying the human 
BDNF Val66Met polymorphism show impaired processing and 
activity-dependent release of BDNF, resulting in synaptic deficits 
and impeded synaptogenesis that ultimately abolish the anti-
depressant behavioral response to ketamine (Liu et al., 2012).
Inhibition of Spontaneous NMDAR-Mediated 
Transmission
Via a different—though not necessarily alternative—mechan-
ism, ketamine has been shown to induce rapid BDNF translation 
in the hippocampus, which depends on reduced phosphoryl-
ation and activation of eukaryotic elongation factor 2 (eEF2) 
(Autry et  al., 2011). Notably, eEF2 kinase knockout animals are 
not sensitive to the acute effects of ketamine administration, 
despite the fact that ketamine would be expected to bind pref-
erentially to NMDARs and affect neuronal NMDAR-mediating 
spontaneous excitatory transmission; at rest, this mechanism 
keeps eEF2 phosphorylated and inhibits BDNF synaptic transla-
tion (Monteggia et al., 2013). De-suppression of BDNF translation 
then contributes to changes in synaptic plasticity that mediate 
ketamine’s antidepressant effects, and AMPAR activation is also 
necessary for these effects. Both mechanisms described above 
could be involved simultaneously and could also be intercon-
nected (for instance, because BDNF stimulates mTORC signaling).
Inhibition of Extrasynaptic NMDARs
Extrasynaptic NMDARs, primarily comprising heterotetramers 
containing GluN2B subunits, are tonically activated by low lev-
els of ambient glutamate. Under baseline conditions, activation 
of cortical extra-synaptic GluN2B-containing NMDARs inhibits 
mTOR-dependent signaling, which suppresses protein synthe-
sis, thereby maintaining synaptic homeostasis (Gray et al., 2011). 
Genetic deletion of GluN2B from principal cortical neurons in 
2BΔCtx knockout mice was shown to mimic and occlude the 
effects of ketamine in suppressing depressive-like behaviors 
and increased the frequency of individual excitatory synaptic 
events onto pyramidal neurons in layers II/III of the PFC (Miller 
et al., 2014). Ketamine rapidly and transiently increased mTOR 
phosphorylation, which is occluded in 2BΔCtx mice (Miller et al., 
2014). These data suggest that GluN2B-containing NMDARs 
may play a role in ketamine’s rapid antidepressant effects due 
to their ability to directly suppress mTOR signaling and limit 
protein synthesis in principal cortical neurons. Miller and col-
leagues found that GluN2B-containing NMDARs are enriched at 
synapses between the medial dorsal thalamus and medial pre-
frontal cortex (mPFC) (Miller et al., 2017). In mice, postdevelop-
mental deletion of GluN2B from pyramidal neurons in the mPFC 
via optogenetic manipulation induced strong antidepressant-
like behavior. The same study found that, interestingly, GluN2B 
deletion had negligible effects on mPFC synaptic inputs from 
the ventral hippocampus. The notion that these networks are 
involved in the action of ketamine and other NMDAR antago-
nists is supported by human (Vollenweider and Kometer, 2010), 
primate (Lv et al., 2016; Maltbie et al., 2016), and rodent studies 
(Dawson et al., 2014; Amat-Foraster et al., 2018; Shen et al., 2018).
Inhibition of Lateral Habenula Neurons
The inhibition of lateral habenula (LHb) glutamatergic neurons 
was recently proposed as an additional NMDAR-dependent 
mechanism. LHb neuronal activity is significantly increased in 
animal models of depression (Yang et al., 2018b) as well as in 
MDD patients (Lawson et al., 2017; Yang et al., 2018a). Activation 
of LHb glutamatergic neurons inhibits the activity of midbrain 
dopaminergic neurons, and ketamine’s rapid antidepressant 
effects are mediated by blockade of NMDAR-dependent burst 
activity in the LHb (Li et al., 2011a). Moreover, local blockade of 
NMDARs or low-voltage-sensitive T-type voltage-sensitive cal-
cium channels in the LHb sufficed to induce rapid antidepres-
sant effects (Yang et al., 2018a). These results suggest a simple 
model whereby ketamine quickly elevates mood by blocking 
the NMDAR-dependent burst activity of LHb neurons and, in 
turn, disinhibits downstream monoaminergic reward centers 
(Yang et al., 2018b). It should be noted, however, that this puta-
tive mechanism of action has only been assessed acutely, at 1 
hour post-ketamine infusion in the LHb; whether this mechan-
ism is active at the peak of ketamine’s sustained antidepressant 
effects (after 24 hours) remains unknown.
GABAB Receptor Expression/Function
GABAB receptors (GABABR) are inhibitory G protein-coupled 
receptors found at both pre- and postsynaptic sites in most 
neurons and glial cells (Padgett and Slesinger, 2010). In a study 
that sheds considerable light onto how NMDAR blockade may 
activate mTOR signaling and downstream pathways, NMDAR 
blockade with AP5 for 90 minutes in cultured hippocampal neu-
rons increased GABABRs on the surface of the dendritic mem-
branes and shifted postsynaptic GABABR function from reducing 
to increasing dendritic resting calcium levels, requiring L-type 
calcium channels in both normal and reduced states of syn-
aptic activity (Workman et  al., 2013, 2018). Mice treated with 
Ro-25-6891, a selective NR2B antagonist, demonstrated that this 
activation of GABABRs was required to stimulate mTOR kinase 
activity and promote the synthesis of synaptic plasticity-related 
proteins (Workman et al., 2013), a typical outcome of ketamine 
treatment. However, there was no direct demonstration that 
ketamine treatment itself engaged this mechanism.
Ketamine’s Mechanisms of Action:  
NMDAR-Independent Mechanisms
Ketamine is a mixture of the 2 enantiomers: (R)- and (S)-
ketamine. While (S)-ketamine has greater affinity for NMDARs, 
(R)-ketamine has better and longer-lasting antidepressant 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy094/5185216 by U
niverità degli Studi di M
ilano user on 30 January 2019
Kadriu et al. | 5
efficacy in rodent models (Zhang et al., 2014; Yang et al., 2015; 
Zanos et  al., 2016). This discrepancy between affinity and 
potency of the 2 enantiomers suggests that ketamine’s antide-
pressant effects do not entirely depend on NMDAR antagonism 
(Zanos and Gould, 2018).
Hydroxynorketamine
After ketamine administration, (2S,6S)- and (2R,6R)-HNK are the 
major metabolites found in the brain and plasma of rodents 
(Zanos et al., 2016) and in the plasma of humans (Moaddel et al., 
2010; Zarate et al., 2012a). To determine whether the metabolism 
of ketamine to HNK is required for its antidepressant actions, 
ketamine was deuterated at the C6 position (6,6-dideuteroketa-
mine), a modification that does not change the affinity of unme-
tabolized ketamine for NMDARs but does slow its metabolism. 
Unlike ketamine, 6,6-dideuteroketamine had no antidepressant 
effects in the forced swim test (FST) or learned helplessness test 
(LHT) at 24 hours (Zanos et  al. 2016). To understand whether 
(2S,6S)-HNK or (2R,6R)-HNK exerted antidepressant effects inde-
pendently of ketamine, their behavioral effects were compared 
in the FST and LHT. Both metabolites had potent antidepressant 
effects, with (2R,6R)-HNK showing greater effects than (2S,6S)-
HNK, in line with previous findings showing that (R)-ketamine 
has greater antidepressant efficacy (Zhang et al., 2014). In add-
ition, while ketamine and (2S,6S)-HNK were both associated 
with increased locomotor activity in the open field test and lack 
of motor coordination in the rotarod test, (2R,6R)-HNK did not 
induce these NMDAR inhibition-mediated side effects in mice 
(Zanos et al., 2016).
These findings demonstrate that a distinct metabolite of 
ketamine was both necessary and sufficient to produce keta-
mine’s antidepressant effects. Interestingly, at relevant con-
centrations (10  mg/kg), (2R,6R)-HNK did not appear to inhibit 
NMDARs (Zanos et al., 2016; Suzuki et al., 2017), implying that 
HNK’s antidepressant effects (and those of ketamine itself) 
do not completely depend on binding to NMDARs. Moreover, 
(2R,6R)-HNK may not inhibit NMDARs; however, this possibility 
was questioned by Suzuki and colleagues (2017), who showed 
that, at concentrations of 50  µM (but not 10  µM), (2R,6R)-HNK 
partially (40%) inhibited NMDAR-dependent currents at rest in 
hippocampal neurons (Suzuki et al., 2017). The authors argued 
that after i.p. administration in mice, a larger proportion of 
ketamine could be metabolized in the liver, thus increasing the 
metabolite’s contribution to antidepressant effects. They fur-
ther suggested that while the initial effects of ketamine could 
be due to the unmetabolized drug, the 24-hour and longer anti-
depressant effects could be due to continued NMDAR inhibition 
by HNK. In contrast, Zanos and colleagues found that, at rele-
vant antidepressant concentrations (10 µM), (2R,6R)-HNK neither 
inhibited NMDARs nor induced any of the side effects typically 
associated with ketamine (Zanos et al., 2016). Clinical trials will 
be required to assess the antidepressant properties of HNK in 
humans.
Stabilization of Glutamate Release/Excitatory 
Transmission
Preclinical evidence suggests that ketamine stabilizes dysfunc-
tion in excitatory (but also inhibitory) transmission within and 
between relevant brain areas involved in the pathophysiology 
of MDD (Thompson et  al., 2015; Duman et  al., 2016; Musazzi 
et  al., 2017; Workman et al., 2018; Zanos et al., 2018b). In par-
ticular, one net effect of ketamine (and its metabolites) seems 
to be sustained activation of AMPAR-mediated excitatory trans-
mission within the mPFC, which results in increased input to 
subcortical areas, thereby impacting stress reactivity and mood.
Early work with classical microdialysis explored the 
actual impact of ketamine on glutamate release in the mPFC 
(Moghaddam et al., 1997), but 2 more recent studies have also 
investigated this phenomenon. One study observed that, 24 
hours after administration of 10 mg/kg (R)-ketamine or (2R,6R)-
HNK, basal glutamate release measured via zero-net-flux quan-
titative microdialysis was significantly increased (Pham et  al., 
2018). Glutamate reuptake was not affected by either ketamine 
or (2R,6R)-HNK. At the same timepoint, the mice showed behav-
ioral improvement in the FST. The authors concluded that mPFC 
activation by ketamine had an excitatory effect and increased 
glutamate release by pyramidal neurons without affecting its 
reuptake, and that the (2R,6R)-HNK metabolite significantly con-
tributed to this effect.
Another study used freshly purified synaptosomes in super-
fusion to explore the effects of racemic ketamine on glutamate 
release in rats vulnerable to the maladaptive effects of chronic 
mild stress (CMS) (Tornese et al., 2017). Different versions of the 
CMS protocol, one of the most popular animal models of depres-
sion, have been used by several groups to investigate ketamine’s 
rapid antidepressant effects (Li et al., 2011b; Ma et al., 2013; Papp 
et al., 2017); such studies typically assess ketamine’s effects in 
a group of stressed animals as a whole. A  recent study used 
the sucrose consumption test for anhedonia to separate vul-
nerable from resilient rats during 5-week CMS (Tornese et  al., 
2017). The investigators found that most stress-induced mal-
adaptive changes in the hippocampus were observed only in 
vulnerable rats. CMS markedly and significantly reduced both 
basal and depolarization-evoked glutamate release. Ketamine 
administration (10  mg/kg) 24 hours before the end of CMS in 
vulnerable rats restored basal glutamate release. Ketamine 
concomitantly restored anhedonic behavior, dendritic atrophy, 
and BDNF mRNA dendritic trafficking (but not BDNF expres-
sion) (Tornese et  al., 2017). These results suggest that one of 
ketamine’s major effects is to restore the basal release of glu-
tamate, which is needed to maintain homeostatic synaptic plas-
ticity (Reese and Kavalali, 2015). Ketamine did not restore BDNF 
expression reduced by CMS but did restore BDNF mRNA den-
dritic trafficking, a process known to be stimulated by chronic 
use of traditional antidepressants as well as physical exercise 
(Baj et al., 2012). The same process was found to be impaired in 
knockin mice carrying the human Val66Met mutation of BDNF 
(Baj et al., 2012; Mallei et al., 2015). It is possible that increased 
BDNF mRNA dendritic trafficking and local translation of BDNF 
protein is crucial for restoring homeostatic synaptic plasticity as 
well as neuroarchitecture (Tornese et al., 2017). These findings 
are in line with the notion that rapid BDNF release is required 
for ketamine’s antidepressant effects (Lepack et al., 2014).
Regulation of the Dopaminergic System
Dysregulation of the dopaminergic system is known to under-
lie the pathophysiology of MDD (Belujon and Grace, 2014, 
2017; Han and Nestler, 2017). Anhedonia—loss of the ability to 
experience pleasure and 1 of the 2 core symptoms of MDD—is 
related to dysregulation of reward-related circuitry that is made 
up of the mesolimbic dopaminergic pathway from the ventral 
tegmental area to the nucleus accumbens as well as multiple 
regulatory pathways. In rodents, these include the infralimbic 
PFC-basolateral amygdala-ventral pallidum (VP) circuit and the 
infralimbic PFC-hippocampus ventral subiculum (Vsub)-nucleus 
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accumbens-VP circuit (Belujon and Grace, 2014, 2017). The first 
circuit reinforces the inhibition of dopaminergic neurons by 
the VP, while the second blocks VP inhibition, increasing dopa-
minergic neuronal activation. Both single and repeated admin-
istration of subanesthetic ketamine (5 mg/kg) rapidly restored 
activation of dopaminergic neurons, which was reduced in rats 
subjected to the LHT. Ketamine administration also improved 
depressive-like behaviors induced by the LHT, and this restora-
tive action was maintained for 24 hours post-ketamine admin-
istration (Belujon and Grace, 2014). Moreover, the rapid and 
sustained antidepressant-like effects of ketamine in the LHT 
also stimulate AMPARs (Koike et al., 2011). It is not clear whether 
ketamine’s regulatory effects on dopaminergic neurons also 
involve NMDAR antagonism. However, these studies suggest 
that an essential restorative action of the dopaminergic system 
also underlies ketamine’s mechanism of action (Kokkinou et al., 
2018).
G Alpha Subunit Translocation-Cyclic Adenosine 
Monophosphate Production
Treatment with different classes of antidepressants has been 
found to increase cellular cyclic adenosine monophosphate 
levels by augmenting the functional coupling of G alpha subu-
nits (Gαs) and adenylyl cyclase after translocation of Gαs from 
lipid raft domains into non-raft regions (Czysz et  al., 2015). 
This hypothesis of antidepressant action has been corrobo-
rated by the finding that the human postmortem brain tissue 
of depressed individuals who committed suicide showed Gαs 
preferentially localized to lipid rafts (Donati et  al., 2008). The 
same authors recently found that treatment of C6 glioma cells 
or primary astrocytes with 10 µM of ketamine for 15 minutes 
induced selective redistribution of Gαs. Moreover, and similar 
to traditional antidepressants, exposure to ketamine elicited a 
sustained increase in cellular cyclic adenosine monophosphate 
attributable to Gαs translocation from lipids rafts (Wray et al., 
2018). The ketamine metabolite (2R,6R)-HNK—which, as noted 
above, has antidepressant effects similar to those of ketamine 
but does not bind to NMDARs—exerted similar effects in cells 
where NMDARs were knocked down to undetectable levels 
(Wray et al., 2018). The authors also found a significant increase 
in BDNF expression in C6 cells 24 hours, but not 1 hour, after 
ketamine treatment (Wray et  al., 2018). Taken together, these 
results suggest that acute ketamine treatment exerts effects 
similar to those of chronic antidepressants via a mechanism 
seemingly independent of NMDAR antagonism.
Reconfiguration of Brain Homeostasis
Both preclinical and clinical studies have demonstrated that 
ketamine administration helps the overall network reconfigur-
ation of disrupted prefrontal connectivity, restoring metabolic 
homeostasis and synchronizing gamma oscillatory activity in 
the brain (Arnsten et al., 2016; Lv et al., 2016; Nugent et al., 2018). 
For example, MDD subjects show enhanced metabolic activity in 
the subgenual cingulate cortex, an area highly associated with 
negative emotions (Mayberg et al., 2005). This symptomatology 
constellation is likely driven by excessive excitatory neuro-
transmission; treatments, like ketamine, that decrease NMDAR-
dependent firing may have a salutary effect at this relevant site 
(Wang and Arnsten, 2015; Arnsten et al., 2016).
Various abnormalities in functional connectivity within the 
PFC and other cortical and subcortical regions have also been 
observed in individuals with MDD (Kaiser et  al., 2015), and 
ketamine administration has been found to enhance normali-
zation of desynchronized global brain connectivity in depressed 
subjects (Abdallah et al., 2017a, 2017b). In vivo evidence of gluta-
mate dysfunction in mood disorders has also been shown using 
proton magnetic resonance spectroscopy, including reduced 
glutamate levels in the dorsolateral PFC of individuals with MDD 
(Yildiz-Yesiloglu and Ankerst, 2006) as well as the dorsomedial 
and dorsoanterolateral PFC (Hasler et al., 2007) and the anterior 
cingulate cortex (Auer et al., 2000).
In addition, studies have suggested that ketamine and 
other glutamatergic modulators exert antidepressant effects 
by increasing synchronization of gamma oscillatory activity in 
the brain (Lazarewicz et al., 2010; Ahnaou et al., 2014; Sanacora 
et al., 2014; Zanos et al., 2016). Although this complex process 
is not entirely understood, multiple mechanisms appear to be 
involved in regulating gamma oscillation, including silencing 
GABAergic inhibition at the synapses and increasing glutamate 
release, thereby increasing AMPAR activation (Ren et al., 2016; 
Zanos et  al., 2018a). This, in turn, induces activity-dependent 
plasticity (Buzsaki and Wang, 2012; Duman and Aghajanian, 
2012). Interestingly, a recent animal study found that the keta-
mine metabolite (2R,6R)-HNK increases gamma oscillations and 
exerts long-lasting antidepressant effects (Zanos et  al., 2016). 
Pretreatment with an AMPAR blocker abolished (2R,6R)-HNK-
induced gamma oscillations and the concomitant antidepres-
sant effects of this metabolite. Relatedly, a recent replication 
study of MDD subjects found that ketamine infusion increased 
gamma oscillatory activity even 6 to 9 hours post-ketamine 
infusion (Nugent et al., 2018). Interestingly, baseline gamma lev-
els appeared to moderate the relationship between increases in 
gamma power post-ketamine and antidepressant response, sug-
gesting that resting gamma oscillations may be a proxy measure 
of inhibition/excitation balance and homeostasis.
The various mechanisms detailed above are not an exhaust-
ive catalog of ketamine’s proposed mechanisms of action. For 
additional data and hypotheses, we direct the interested reader 
to several recent reviews on the subject (Miller et al., 2016; Lener 
et al., 2017; Strasburger et al., 2017; Abdallah et al., 2018; Zanos 
and Gould, 2018). It should also be noted that, despite all the 
research recently done, the mechanisms underlying ketamine’s 
antidepressant effects are not yet entirely clear and could be 
even more complex than those of traditional antidepressants.
Ketamine: Clinical Evidence
The discovery that the prototypic glutamatergic modulator 
ketamine has antidepressant effects was hailed as arguably 
one of the most important recent discoveries in psychiatry 
(Insel, 2014a). In addition to the putative mechanisms of actions 
described above, ketamine’s mechanistic processes also include 
potential sigma-1 and mu-opioid receptor activation. As noted 
above, ketamine exists as a mixture of 2 enantiomers—(R) and 
(S)—that show different affinity for glutamate receptors (Mion 
and Villevieille, 2013). (S)-ketamine has been studied in a num-
ber of clinical trials (described below), but no clinical trials to 
date have investigated the efficacy of (R)- vs (S)-ketamine.
Berman and colleagues initially found that a single, subanes-
thetic-dose ketamine infusion had rapid antidepressant effects 
(Berman et al., 2000). Subsequently, Zarate and colleagues con-
ducted a series of randomized controlled studies establishing 
that subanesthetic-dose ketamine (0.5 mg/kg, i.v.) administered 
over 40 minutes led to rapid, robust, and relatively sustained 
antidepressant effects in TRD—both MDD (Zarate et  al., 2006; 
Diazgranados et al., 2010a; Ibrahim et al., 2011; Iadarola et al., 
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2015) and bipolar depression (Diazgranados et al., 2010b; Zarate 
et al., 2012b). In research settings, studies of TRD patients found 
a response rate to this ketamine dose of more than 70% within 
24 hours post-infusion (Zarate et al., 2006), with about 50% to 
70% exhibiting a variable duration of response (aan het Rot 
et al., 2010; Wan et al., 2015). At this dose, ketamine was also 
shown to have superior antidepressant effectiveness over the 
benzodiazepine midazolam, which was used as an active pla-
cebo comparator to mimic ketamine’s sedative and anxiolytic 
effects; roughly 65% of patients achieved a ≥50% reduction in 
Montgomery-Asberg Depression Rating Scale (MADRS) score 
in response to ketamine compared with approximately 28% of 
patients receiving midazolam (Murrough et al., 2013b). Building 
on this work, numerous meta-analyses have corroborated the 
antidepressant effects of ketamine in both MDD and bipolar 
depression (Caddy et al., 2014; McGirr et al., 2015; Newport et al., 
2015; Romeo et al., 2015; Kishimoto et al., 2016).
Further studies established that off-label ketamine use is also 
associated with significant and rapid (1–4 hours) antisuicidal 
effects (Price et al., 2009; Diazgranados et al., 2010a; Murrough 
et al., 2015). Indeed, a recent meta-analysis of 167 patients with 
a range of mood disorder diagnoses found that ketamine was 
associated with reduced suicidal thoughts compared with pla-
cebo; these effects occurred as rapidly as within a few hours 
and lasted up to 7 days (Wilkinson et al., 2018). Ketamine also 
appears to have pan-therapeutic effects, improving mood symp-
toms across a variety of diagnoses, including anhedonia (Lally 
et al., 2014), fatigue (Saligan et al., 2016), obsessive-compulsive 
disorder (Bloch et  al., 2012; Rodriguez et  al., 2013), and post-
traumatic stress disorder (Feder et  al., 2014; Hartberg et  al., 
2018). While a full review of ketamine’s antidepressant effects is 
beyond the scope of this article, the interested reader is referred 
to several recent reviews of this subject (Abdallah et al., 2018; 
Molero et al., 2018).
Despite ketamine’s robust antidepressant effects, response is 
transient and the remission period after a single infusion is rela-
tively short (days to weeks). To prolong ketamine’s antidepres-
sant efficacy, multiple doses have been clinically studied to 
determine the safety, tolerability, and efficacy of repeat-dose i.v. 
ketamine. To date, the preliminary data suggest that up to two 
to three 0.5-mg/kg i.v. infusions per week for 2 weeks are well-
tolerated and effective (aan het Rot et al., 2010; Rasmussen et al., 
2013; Diamond et al., 2014). In one study, 10 medication-free TRD 
patients who had previously responded to ketamine were given 
6 infusions (0.5 mg/kg, i.v. over 40 minutes) for 12 days (aan het 
Rot et  al., 2010). Minor adverse effects were associated with 
repeat dosing. Interestingly, 9 of the 10 patients met response 
criteria after the first as well as the sixth infusion; however, 8 
of those 9 patients relapsed, on average, 19 days after the sixth 
infusion. Other preliminary studies have similarly established 
that repeated ketamine infusions are superior to a single dose 
and may be a potential avenue for extending ketamine’s anti-
depressant actions for up to several months (Murrough et  al., 
2013a; Rasmussen et al., 2013; Shiroma et al., 2014; Singh et al., 
2016b). For instance, a recent, randomized, multicenter, double-
blind study assessed change in MADRS score in 68 MDD patients 
(Singh et al., 2016b); MADRS scores improved from baseline to 
day 15 in those receiving ketamine vs placebo: −18.4 (SD = 12.0) 
for ketamine administered twice weekly for 2 weeks vs −5.7 
(SD = 10.2, P < .001) for placebo, and −17.7 (SD = 7.3) for ketamine 
administered thrice weekly vs −3.1 (SD = 5.7, P <  .001) for pla-
cebo. No difference in MADRS score was observed between the 
2 dosing frequencies, and no difference in the number of treat-
ment-based adverse effects was reported. Transient dissociative 
symptoms appeared to lessen with repeated dosing (Singh et al., 
2016b). Another study reported similar decreases in MADRS 
scores (18.9, SD  =   6.6, P <  .001) when assessing the effects of 
open-label ketamine infusion 6 times over 12 days in a group of 
24 individuals with TRD (Murrough et al., 2013b). Another recent, 
double-blind, crossover trial using active placebo (midazolam) 
in 40 TRD subjects found that repeated (twice to thrice weekly) 
ketamine (0.5 mg/kg) infusions maintained and prolonged ini-
tial antidepressant response to a single infusion (Phillips et al., 
2018). However, a recent, small, double-blind, placebo-controlled, 
add-on therapy study in outpatient TRD subjects with chronic, 
recurrent suicidal ideation found that ketamine did not separ-
ate from placebo in ameliorating depressive symptoms (P = .47) 
or suicidal ideation (P = .32) (Ionescu et al., 2019). Although the 
underlying strategy for maintaining this response is still lacking, 
it is worth noting that several studies are currently underway 
that may further inform efforts to prolong ketamine’s effects; 
results are not yet publicly available.
To address ketamine’s potential adverse effects, investiga-
tors are increasingly exploring other potent and effective alter-
native—and largely more convenient—means of ketamine 
administration. These include intranasal (Lapidus et al., 2014), 
intramuscular (Glue et al., 2011), oral (Irwin et al., 2013), and sub-
lingual (Lara et al., 2013) routes. One study found that sublin-
gual ketamine had antidepressant effects in 20 of 27 patients 
(77%), with only mild adverse effects (Lara et al., 2013). Evidence 
from small case studies also suggests that oral ketamine may be 
effective. In one such study, 14 patients receiving hospice care 
demonstrated improvements in both mood and anxiety symp-
toms after 28  days of open-label oral ketamine (Irwin et  al., 
2013). Intramuscular ketamine—which does not require special-
ized equipment to administer—has also been studied. This route 
of administration has similar bioavailability to i.v. ketamine, in 
contrast to sublingual and oral ketamine, which have bioavail-
ability of 30% and 20%, respectively. A small study of 2 female 
TRD subjects who received open-label intramuscular ketamine 
found that the patients responded in a dose-dependent man-
ner (Glue et al., 2011). Finally, a randomized, double-blind, cross-
over, placebo-controlled trial of 50  mg of intranasal ketamine 
found that, at this dose, intranasal ketamine had antidepressant 
effects that appeared within 24 hours; minimal dissociative and 
psychotomimetic effects were observed (Lapidus et  al., 2014). 
Despite these promising preliminary results, larger, controlled 
studies are needed to assess whether these alternative routes 
of administration will exert the same robust antidepressant 
effects as i.v. ketamine.
Taken together, the results reviewed above suggest that 
ketamine may not only ameliorate depressive symptoms within 
hours of administration but that its effects may be sustained 
when administered over multiple sessions. While these data are 
promising, ketamine-induced side effects—though transient in 
nature—must be seriously considered, especially in the absence 
of well-controlled longitudinal studies that assess this question.
(S)-Ketamine Hydrochloride
Clinical trials of the (S)-ketamine hydrochloride (esketamine) 
enantiomer of ketamine to treat TRD are underway. A  multi-
center, randomized, placebo-controlled trial (NCT0160080) with 
30 TRD patients receiving i.v. infusions of 0.2 mg/kg and 0.4 mg/
kg of esketamine, respectively, found that subjects experienced 
significant relief in their depressive symptoms (as evidenced 
by a decrease in MADRS score) within 2 hours of administra-
tion; those effects were sustained for three days and, in some 
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patients, lasted for up to 2 weeks following a single infusion 
(Singh et  al., 2016a). In that study, esketamine’s side effects—
which include nausea, headache, and dissociation—appeared 
to be milder than those observed in response to i.v. keta-
mine. Another recent multisite, randomized, phase 2 study 
(SYNAPSE, NCT01998958) examined the antidepressant effi-
cacy of intranasal esketamine (28  mg, 56  mg, or 84  mg) in 67 
patients with TRD. Those who received intranasal esketamine 
at doses of 56 or 84 mg plus an oral antidepressant showed sig-
nificant improvement in depressive symptoms (as measured by 
change in MADRS total score from baseline to day 8, the pri-
mary endpoint) compared with those who received matching 
placebo (Daly et al., 2018). Interestingly, esketamine was super-
ior to placebo in all 3 esketamine groups (28  mg, 56  mg, and 
84 mg), with a significant ascending dose-response relationship. 
Another similarly designed proof-of-concept, multisite, 4-week, 
double-blind study compared standard treatment plus intrana-
sal esketamine (84  mg) with standard treatment plus placebo 
in individuals with MDD at imminent risk of suicide. The study 
involved 68 participants randomly assigned to 1 of 2 groups who 
received either esketamine or placebo twice a week for 4 weeks 
in addition to standard-of-care treatment; all participants con-
tinued to receive standard antidepressant treatment through-
out the study. The researchers assessed the effects of intranasal 
esketamine at 4 hours, 24 hours, and 25  days post-treatment. 
The study found that, compared with the placebo group, depres-
sion rating scale scores were significantly improved post-esket-
amine at 4 hours and at 24 hours, and that suicidal ideation was 
reduced; esketamine’s effects did not differentiate from placebo 
at 25 days (Canuso et al., 2018).
Based on this evidence, esketamine is currently in phase 
3 clinical trials for the treatment of TRD (NCT02417064, 
NCT02497287, NCT02418585) and received breakthrough ther-
apy designation from the FDA. If ongoing studies are positive, 
approval will likely be fast-tracked.
Additional Agents Targeting NMDARs
Dextromethorphan, Dextromethorphan-Quinidine, 
and Dextromethorphan-Bupropion
The cough suppressant dextromethorphan is a noncompetitive, 
nonselective NMDAR antagonist that shares some of ketamine’s 
rapid-acting antidepressant properties (Lauterbach, 2011, 2012). 
Its mechanism of action is largely unknown, though preclin-
ical mouse studies showed that sigma-1 receptor activation is 
required for the antidepressant-like effects of dextromethor-
phan in the FST (Nguyen et al., 2014). The same group recently 
reported that dextromethorphan’s antidepressant effects also 
depend on AMPARs (Nguyen and Matsumoto, 2015) as well as 
the nitric oxide/cyclic guanosine monophosphate pathway 
(Sakhaee et al., 2017).
A randomized, placebo-controlled trial of dextromethorphan 
explored its use as an adjunct to valproate in bipolar depression. 
No significant differences were observed between groups on 
the outcome measures of interest (mean Hamilton Depression 
Rating Scale [HAM-D] and Young Mania Rating Scale scores), 
potentially due to metabolism-related reductions in drug con-
centration (Lee et al., 2012). To date, no randomized controlled 
trials have explored the use of dextromethorphan as monother-
apy for the treatment of depression.
A dextromethorphan-quinidine combination is also being 
studied for TRD under the name Nuedexta (AVP-923), which 
is FDA approved for the treatment of pseudobulbar affect. 
The addition of low-dose quinidine (a CYP2D6 enzyme inhibi-
tor) to dextromethorphan increases the bioavailability of this 
agent. A retrospective chart review of 22 subjects with bipolar 
disorder-I or bipolar disorder not otherwise specified found that 
20  mg of dextromethorphan and 10  mg of quinidine once or 
twice daily, when added to a current medication regimen over a 
90-day treatment period, significantly improved Clinical Global 
Impression scale scores (Kelly and Lieberman, 2014). Another 
case report found that Nuedexta had antidepressant effects in a 
depressed patient with emotional lability (Messias and Everett, 
2012). Finally, an open-label, one-arm trial of 20 patients with 
TRD who received oral doses of Nuedexta (45  mg and 10  mg, 
respectively) every 12 hours found that, after 10 weeks, 45% of 
subjects had experienced remission and 35% had experienced 
response, results that can be considered modest for an open-
label trial; 6 subjects discontinued before study completion 
(Murrough et  al., 2017b). Mild side effects have been reported 
with Nuedexta, including gastrointestinal complaints, dizzi-
ness, and sedation, and one patient experienced severe insom-
nia (Murrough et al., 2017b).
Another related compound is AVP-786, an experimental 
compound formed by combining deuterium-modified dex-
tromethorphan hydrobromide (to reduce first pass metabolism) 
and ultra-low dose quinidine sulfate (an inhibitor of the enzyme 
CYP 2D6 used to increase bioavailability). A recent 10-week, mul-
ticenter, randomized, double-blind, placebo-controlled clinical 
trial (NCT02153502) evaluated the efficacy, safety, and tolerabil-
ity of AVP-786 as adjunctive therapy in patients with TRD, but 
results have not yet been released.
Finally, the related compound AXS-05 contains both dex-
tromethorphan and bupropion (a norepinephrine and dopa-
mine reuptake inhibitor currently approved for the treatment 
of depression). Bupropion may work to increase the bioavail-
ability of dextromethorphan in the brain, and AXS-05 may offer 
a theoretical advantage in patients at risk of overdose or with 
cardiac conduction concerns. AXS-05 is currently in phase 3 
trials (NCT02741791). This randomized, double-blind, placebo-
controlled, 12-week study comprises a 6-week, open-label 
bupropion lead-in period followed by a 6-week, double-blind 
treatment period. This ongoing study seeks to assess the effi-
cacy of AXS-05 augmentation with bupropion vs bupropion 
monotherapy in patients with TRD, but no results have yet been 
posted.
Lanicemine (AZD6765)
Lanicemine (formerly known as AZD6765) possesses rapid anti-
depressant effects. It is a moderate-affinity, low-trapping NMDAR 
antagonist, but no preclinical mechanistic studies are available 
to confirm its mechanism of action. An initial study of 22 med-
ication-free subjects with TRD showed that a single lanicemine 
infusion (150 mg) was more effective than placebo (Zarate et al., 
2013). Lanicemine’s antidepressant effects occurred within 
80 minutes of a single administration and lasted for approxi-
mately 2 hours, with no dissociative symptoms noted. However, 
the study concluded that symptom improvement was transi-
ent and short-lived. A  subsequent 3-week, placebo-controlled 
trial studied repeated-dose adjunctive lanicemine infusions in 
subjects with TRD. Lanicemine, which was given at 2 different 
doses (100 mg and 150 mg), again demonstrated antidepressant 
effects without ketamine-like side effects, but these were not 
rapid-acting (Sanacora et al., 2014). Finally, in a larger, 6-week, 
phase 2b study, adjunctive repeated-dose (50 mg and 100 mg) 
lanicemine did not separate from placebo, possibly due to the 
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large placebo effect (39% at trial endpoint) (Sanacora et al., 2017). 
Thus, despite the fact that lanicemine was well tolerated and 
caused no psychotomimetic or dissociative side effects, the evi-
dence from large clinical trials suggests that this agent did not 
separate from placebo (Sanacora and Schatzberg, 2015; Sanacora 
et al., 2017). Based on this evidence, clinical development of lan-
icemine was discontinued.
Subunit NR2B-Specific NMDAR Antagonists
The mechanism of action of NR2B-specific NMDA antagonists 
is thought to be similar to that of ketamine (Miller et al., 2014); 
however, few preclinical studies have been conducted to con-
firm this hypothesis.
CP-101,606/Traxoprodil
CP-101,606 is a nonselective, NR2B-specific, NMDAR antagon-
ist with some sigma receptor effects. In a randomized, double-
blind, placebo-controlled study of 30 TRD patients, monotherapy 
with CP-101,606 had significant antidepressant effects, as evi-
denced by a 50% reduction in HAM-D scores at day 5. Notably, 
investigators found a 60% response rate in patients receiving 
CP-101,606 compared with 20% in the matched placebo group; 
this effect lasted at least a week in 78% of treatment responders 
(Preskorn et al., 2008). However, during the trial, dissociative side 
effects were prominent and required both dose reductions and 
slower infusions, underscoring that NR2B antagonists also have 
dissociative side effects. Ultimately, development of this com-
pound was discontinued due to cardiotoxicity (specifically, QTc 
prolongation) in certain patients.
MK-0657 (CERC-301)
In a 12-day, double-blind, randomized, placebo-controlled, 
crossover pilot study of 5 TRD patients, the oral NR2B antagon-
ist MK-0657 showed no antidepressant effects over placebo on 
the primary efficacy measure; however some improvement in 
antidepressant symptoms was observed when other depression 
rating scales—specifically the HAM-D and the self-reported Beck 
Depression Inventory—were used (Ibrahim et al., 2012a). No ser-
ious or dissociative adverse effects were noted.
MK-0657, subsequently known as CERC-301, received fast-
track designation for the treatment of MDD. Results from a 
phase 2 trial (NCT02459236) using 12 or 20 mg of CERC-301 found 
that this agent did not achieve primary endpoint efficacy due to 
its lack of significant antidepressant effects. However, it is worth 
noting that the 20 mg dose at day 2 did show some clinically 
meaningful antidepressant effects, though these did not reach 
statistical significance (https://ir.cerecor.com/press-releases/
detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-
study). Another 28-day phase 2 study of adjunctive CERC-301 in 
patients with severe MDD with suicidal ideation (NCT01941043) 
found that 8 mg of CERC-301 had no significant antidepressant 
effects (Paterson et al., 2015).
NMDAR And/Or Glycine Site Modulators
D-Cycloserine
D-cycloserine (DCS) is a partial agonist at NMDARs containing 
GluN2A and GluN2B subunits, and a full agonist at the GluN2C 
and GluN2D subunits (Sheinin et  al., 2001). It is thought to 
exert its antidepressant effects by attenuating the function of 
NMDAR-bearing GluN2A or GluN2B subunits, though it remains 
unknown whether DCS’s agonist or antagonist properties 
account for its antidepressant efficacy; no relevant preclinical 
mechanistic studies are available.
In a placebo-controlled trial, 250 mg/day of adjunctive DCS 
had no significant  antidepressant effects in 22 patients with 
TRD (Heresco-Levy et al., 2006). Interestingly, a second study of 
26 TRD patients explored escalating-dose adjunctive DCS (up to 
1000 mg/day) and found that one-half of the participants had 
a significant antidepressant response to DCS, as measured by 
the HAM-D and Beck Depression Inventory (Heresco-Levy et al., 
2013).
A subsequent open-label study investigated adjunctive 
DCS as a maintenance treatment after a single ketamine infu-
sion in 12 patients with bipolar depression (n = 7 completers) 
(Kantrowitz et al., 2015). Depressive symptoms improved from 
baseline through week 8 (except at the 2-week timepoint), and 
a large effect size was seen at day 1. Four of the 7 patients who 
completed the study remained in remission after 8 weeks. 
Furthermore, clinical improvement at the 8-week timepoint 
correlated with magnitude of improvement 24 hours post-ket-
amine. However, interpretation of the efficacy of this agent is 
limited by the fact that this study had no control group.
In a recent meta-analysis that drew its data from the studies 
cited above, DCS was linked to acute antidepressant response 
at high doses (1000 mg) but not at low doses (250 mg) (Newport 
et al., 2015).
GLYX-13 (Rapastinel)
GLYX-13 is a glycineB-like functional partial agonist. In preclin-
ical studies, GLYX-13 was found to exert rapid antidepressant-
like effects without the dissociative and sedative side effects of 
ketamine (Burgdorf et al., 2013). Proposed mechanisms of action 
for this agent include directly modulating NR2B-containing 
NMDARs (Burgdorf et  al., 2013), improving hippocampal long-
term potentiation (Burgdorf et al., 2015), and enhancing BDNF 
exocytosis via voltage-gated calcium channels and TrkB signal-
ing (Kato et al., 2017) as well as via the mTORC1 pathway (Liu 
et al., 2017). In addition, recent theories regarding the mechan-
ism of action of GLYX-13 have evolved and implicate NMDAR 
activation (Zanos et al. 2018a).
Clinically, one large phase 2b study randomized 116 unmed-
icated TRD patients to receive GLYX-13 i.v. at doses of either 
1, 5, 10, or 30 mg/kg or placebo over 3 to 15 minutes. Patients 
in the 5-mg/kg and 10-mg/kg groups had the most significant 
antidepressant response, and no serious adverse effects were 
reported (Moskal et al., 2014). Building on this work, the same 
investigators then studied adjunctive GLYX-13 in a randomized, 
double-blind study of 116 TRD patients (Preskorn et al., 2015). 
Subjects were randomized to weekly infusions of i.v. GLYX-13 at 
doses of 1, 5, or 10 mg/kg or placebo. After an interim safety and 
efficacy analysis, an additional cohort was added who received 
i.v. GLYX-13 (30 mg/kg) or placebo. As with the first study, those 
who received 5 or 10  mg/kg of i.v. GLYX-13 had significantly 
reduced HAM-D scores compared with placebo. No antidepres-
sant effects were observed after day 7. Due to these promising 
preliminary findings, GLYX-13 received breakthrough therapy 
designation from the FDA for adjunctive treatment of MDD. 
A number of clinical trials looking at the safety and efficacy of 
GLYX-13 as monotherapy or adjunctive treatment in subjects 
with MDD and suicidality are underway (active trials available 
at https://clinicaltrials.gov/ct2/results?cond=&term=rapastinel
&cntry=&state=&city=&dist=).
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Sarcosine
Sarcosine is a glycine transporter-1 inhibitor whose mechanism 
of action is thought to depend on NMDAR modulation, though 
no mechanistic studies are available to confirm this hypothesis.
In a 6-week, randomized, double-blind, citalopram-controlled 
clinical trial of 40 patients with MDD, sarcosine was associated 
with higher remission and response rates than the selective sero-
tonin reuptake inhibitor citalopram, as assessed by the HAM-D 
and other rating scales. Furthermore, those treated with sarcosine 
were less likely to drop out of the study. No significant adverse 
effects were reported (Huang et al., 2013). No active studies are 
presently investigating use of this agent for depression.
AV-101
AV-101 is a novel prodrug that crosses the blood brain barrier, 
where it is converted to 7-Chlorokynurenic acid, a potent and 
highly selective competitive glycine binding site antagonist at 
the NMDAR (Wallace et  al., 2017); no preclinical mechanistic 
studies have explored its mechanism of action.
Two independent phase 2 trials are underway. The first is an 
NIMH-funded, randomized, controlled trial studying the effi-
cacy of AV-101 in TRD individuals who will receive 2 weeks of 
either 1080 mg/day or 1440 mg/day of AV-101. The primary out-
come measure is change in HAM-D total score (NCT02484456). 
Another larger, multicenter, randomized, placebo-controlled 
clinical trial is examining the efficacy and safety of adjunctive-
use oral AV-101 in 180 patients with TRD. Patients will concomi-
tantly receive either a selective serotonin reuptake inhibitor 
or a serotonin norepinephrine reuptake inhibitor. The primary 
outcome measure is change from baseline to study endpoint as 
measured by the MADRS (NCT03078322).
Metabotropic Glutamate Receptors
The metabotropic glutamate receptors (mGluRs) are expressed 
widely throughout the brain and modulate the glutamate sign-
aling pathway outside of the NMDAR and AMPAR pathways.
Several preclinical studies have explored the antidepressant 
effects of mGluR modulators. In this context, AMPAR stimula-
tion was consistently found to be necessary for the antidepres-
sant effects of mGluR2/3 antagonists (Karasawa et  al., 2005; 
Witkin et al., 2016). At the synaptic level, both BDNF/TrkB sign-
aling and the mTORC1 pathway were also found to be key to 
the antidepressant effects of mGluR2/3 antagonists, echoing 
the antidepressant effects of other glutamatergic agents (Koike 
et al., 2011). The antidepressant effects of presynaptic mGluR2 
agonists would hypothetically occur by reducing excessive glu-
tamate release; in contrast, GluR2/3 antagonists are thought to 
enhance synaptic glutamate levels, thereby boosting AMPAR 
transmission and firing rates and extracellular monoamine 
levels. Interestingly, the antidepressant effects of mGluR5 nega-
tive allosteric modulators (NAMs) were found to not depend on 
AMPA, TrkB, or mTOR activation, suggesting that these agents 
act through mechanisms distinct from those of ketamine (Iijima 
and Fukumoto, 2012; Palucha-Poniewiera et al., 2014).
Several agents that act as positive allosteric modulators or 
NAMs have been studied in TRD.
AZD2066
The mGluR5 NAM AZD2066 was studied in a randomized con-
trolled trial that compared its efficacy with both placebo and 
duloxetine, a serotonin norepinephrine reuptake inhibitor 
(NCT01145755). No significant difference was observed between 
the 3 arms of the study (results available at https://clinicaltrials.
gov/ct2/results?cond=depression&term=AZD2066&cntry=&sta
te=&city=&dist=). No active studies are presently investigating 
use of this agent for depression.
RO4917523/Basimglurant
The potential antidepressant effects of the mGluR5 NAM 
basimglurant were studied in a 9-week, phase 2, randomized, 
multicenter trial of 333 TRD patients (Quiroz et al., 2016). No sig-
nificant difference in MADRS score was observed between the 
3 treatment arms (placebo, adjunctive basimglurant 0.5 mg, or 
adjunctive basimglurant 1.5 mg) (NCT00809562). No active stud-
ies are presently investigating use of this agent for depression.
JNJ40411813/ADX71149
The potential antidepressant effects of JNJ40411813, a novel 
mGluR2 PAM, were investigated in a phase 2a, randomized, mul-
ticenter, double-blind, proof-of-concept study. JNJ40411813 was 
administered as an adjunctive treatment to 121 MDD subjects who 
also had significant anxiety symptoms. No significant change in 
MADRS score was observed between the different treatment arms 
of the study (NCT01582815) (Kent et al., 2016). No active studies are 
presently investigating use of this agent for depression.
RO4995819
RO4995819 is an mGluR2/mGluR3 antagonist and a negative 
allosteric modulator. In a randomized, double-blind, placebo-
controlled study of 357 TRD patients, RO4995819 (at doses of 
5, 15, or 30 mg) had no antidepressant effects compared with 
placebo, as measured by change in MADRS score (NCT01457677; 
results available at https://www.roche.com/dam/jcr:75711f62-
3d1f-46b5-a7b1-87b92fd40e7b/en/irp150128.pdf). No active stud-
ies are presently investigating use of this agent for depression.
Other Glutamatergic Modulators
Riluzole
The pharmacological profile of riluzole includes inhibiting voltage-
dependent sodium channels in neurons (Urbani and Belluzzi, 2000). 
It also exerts a range of effects on the glutamatergic system, such 
as increasing synaptic AMPAR trafficking (Du et al., 2007), stimulat-
ing neurotrophic factor synthesis (Mizuta et al., 2001), enhancing 
synaptic glutamate reuptake (Frizzo et al., 2004), and reversing dys-
functional metabolism in glia (Banasr et al., 2010).
Riluzole, which is FDA-approved for the treatment of amyotrophic 
lateral sclerosis, has also been used to treat both refractory obsessive-
compulsive disorder and depression. While initial results of riluzole 
use in TRD were promising (Zarate et al., 2004), many subsequent 
randomized, placebo-controlled trials found that antidepressant 
response to this agent failed to separate from placebo. This includes 
trials of riluzole as monotherapy in bipolar depression (Park et al., 
2017), as an add-on to potentially extend ketamine’s antidepressant 
effects in TRD (Ibrahim et al., 2012b), and as augmentation treatment 
in a parallel comparison design study of TRD (Mathew et al., 2017).
Diazoxide
Diazoxide is known to increase glutamate uptake from the syn-
aptic cleft by activating the KATP channel to chronically increase 
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expression of the excitatory amino acid transporter-2 system in 
glial cells. The excitatory amino acid transporter-2 transporter, 
which is predominantly expressed on astroglial cells and is 
responsible for 90% of the total glutamate uptake in the synap-
tic cleft, is one of the major glutamate transporter systems (Kim 
et  al., 2011). However, a recent phase 2, randomized, placebo-
controlled trial of diazoxide in TRD was halted due to major side 
effects and intolerability (NCT02049385) (Kadriu et al., 2018).
Conclusion
Here, we have reviewed the clinical evidence supporting the use 
of novel glutamatergic agents for the treatment of TRD and also 
discussed their putative mechanisms of action. Over the past 2 
decades, the findings reviewed above have fundamentally shifted 
our understanding of the pathophysiology of depression and are 
informing the development of novel glutamatergic-based agents 
that act more rapidly than currently available monoaminergic-
based agents (Sanacora et al., 2008, 2012; aan het Rot et al., 2010; 
aan het Rot et al., 2012; Musazzi et al., 2013; Insel, 2014b; Park et al., 
2015)—indeed, a number of these therapies act within hours to 
days instead of weeks to months. As a result of these promising 
findings, novel paradigms of rapid antidepressant response are 
currently being adapted in nonexperimental clinical settings to 
treat acute depressive symptoms, suicidality, and TRD. In addition, 
some of these agents have been awarded breakthrough therapy 
status by the FDA, including esketamine, GLYX-13, and AV-101.
Given the complexity of mood disorders, many questions 
nevertheless remain unanswered. For instance, what popu-
lations are these agents best suited for? Can ideal candidates 
for novel therapeutics be identified by genotype, serum mark-
ers, or neuroimaging modalities? What neural perturbations 
are specific to those who respond—as opposed to those who 
do not respond—to ketamine (or esketamine, GLYX-13, AV-101, 
etc)? Do different treatment modalities share common under-
lying mechanisms? How can we reduce the high relapse rates 
associated with these rapid-acting treatments? Despite these 
questions, the future of novel, rapid-acting, glutamate-based 
antidepressants is bright. Continued investigation into this rap-
idly growing research area will improve our understanding of 
the utility and safety of the multiple agents reviewed above in 
order to confirm their antidepressant efficacy in larger samples 
and further clarify their underlying mechanisms of action.
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